Saturday 17 October 2026 Export YCBD’s income statement to Excel — free account

cbdMD, Inc.

YCBD Healthcare Drug Manufacturers Specialty & Generic

cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024. In the quarter to June 2026, revenue grew 20.6%, EPS grew 47.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%

Follow YCBD

Alert me

Market cap: $4.0M
P/E: 41.2×
Fwd P/E: −3.8×
Dividend yield: —
F-score: 6/9
Altman Z: −21.65
Beneish M: −2.51
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.28

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 5.15%

Capital & Financial Ratios $m

Market Cap 4.04

Revenue 20.93

Net Income (2.89)

Free Cash Flow (2.41)

Net Debt (2.12)

Current Ratio 2.50

Debt/Equity 0.00

P/E ratio 41.18

Fwd P/E (3.81)

P/S ratio 0.18

P/B ratio 0.45

Past 5Y EPS Growth —

This Y EPS Growth 69.72%

Next Y EPS Growth 42.42%

Next Y revenue growth 14.22%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 25.59%

10-year low 10-year high

P/B against its own 10 years 17.56%

10-year low 10-year high

EV/Sales against its own 10 years 25.10%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	2	2	2
Receivables	1	1	1	2
Inventory	4	2	3	3
Other	—	—	—	—
	8	6	7	8

	2023	2024	2025	Q'26
Payables	2	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	5	9	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	(14.45%)	(18.46%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(38.05%)	(38.74%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	5	6	6	—	—
’25	5	5	5	5	19
’24	5	4	5	5	19
’23	6	6	6	6	24
’22	9	10	9	8	35
’21	12	12	11	10	44
’20	10	9	11	12	42

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(1)	(1)	0	—	—
’25	0	0	(1)	0	(1)
’24	0	(1)	0	0	0
’23	(2)	(2)	0	0	(4)
’22	(5)	(5)	(2)	(2)	(15)
’21	(2)	(3)	(5)	(4)	(14)
’20	(5)	(4)	(1)	0	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(1)	(1)	0	—	—
’25	0	0	(1)	0	(2)
’24	0	(1)	0	0	(1)
’23	(2)	(2)	0	0	(5)
’22	(6)	(5)	(3)	(2)	(16)
’21	(2)	(3)	(5)	(4)	(14)
’20	(5)	(6)	(1)	0	(12)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.04)	(0.08)	(0.11)	—	—
’25	(1.76)	(1.90)	(0.21)	0.24	(1.09)
’24	(5.36)	(10.80)	(1.20)	2.94	(14.32)
’23	(28.83)	(13.92)	(9.28)	(72.48)	(106.56)
’22	(126.13)	(36.04)	(198.20)	(90.09)	(446.85)
’21	(64.86)	(86.49)	7.21	(14.41)	(169.37)
’20	162.16	144.14	(64.86)	(57.66)	100.90

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	1,440.00	914.40	790.56	180.72	367.20	72.00	4.48	2.49	0.47	Analyst estimates 2026–2028 Powerpack
	High	—	2,116.80	3,052.80	2,606.40	1,476.00	2,458.80	468.00	136.44	10.72	6.54
People
People	Employees	10	11	7	182	165	154	90	52	42	42
	Revenue/emp, $m	0.20	0.41	0.07	0.13	0.25	0.29	0.39	0.46	0.46	0.46
Income, $m
Income, $m	Revenue	2	4	0	24	42	44	35	24	19	19
	Gross margin, %	20.33	69.71	77.35	61.37	62.96	67.41	63.09	62.01	61.57	62.37
	EBT	(4)	(1)	(2)	(48)	11	(24)	(70)	(23)	(4)	(2)
	EBT margin, %	(191.39)	(30.42)	(391.44)	(202.05)	26.99	(54.61)	(197.96)	(94.96)	(18.99)	(10.63)
	Net income	(4)	(1)	0	(51)	13	(23)	(70)	(23)	(4)	(2)
	Depreciation	0	0	0	1	2	3	65	16	2	2
Per share, $
Per share, $	Revenue	244.77	355.16	21.35	476.85	341.91	291.68	213.27	95.55	36.14	4.77
	Earnings	(471.13)	(110.39)	(18.02)	(1,016.22)	100.90	(169.37)	(446.85)	(106.56)	(14.32)	(1.09)
	Cash flow	(349.07)	(184.90)	(259.21)	(310.03)	(87.06)	(92.42)	(90.16)	(17.02)	(0.65)	(0.36)
	Capex	(15.34)	(0.63)	(17.84)	(25.17)	(10.78)	(2.24)	(4.15)	(1.18)	(0.54)	(0.05)
	Free cash flow	(364.41)	(185.54)	(277.06)	(335.20)	(97.83)	(94.66)	(94.31)	(18.19)	(1.19)	(0.41)
	Book value	(35.27)	408.64	652.06	758.15	646.38	676.34	189.30	35.73	3.64	1.80
	Shares, m	0	0	0	0	0	0	0	0	1	4
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	3.77	0.00	0.00	0.00	0.00	0.00
	P/S	5.60	5.60	100.99	2.99	2.11	2.57	0.38	0.09	0.10	0.25
	P/B	4.89	4.89	3.31	1.88	1.11	1.11	0.43	0.23	1.04	0.67
	EV/Sales	5.60	5.60	88.58	2.81	1.79	1.98	0.19	0.06	0.10	0.26
	EV/FCF	(10.82)	(10.82)	(6.83)	(3.99)	(6.22)	(6.07)	(0.44)	(0.29)	(3.23)	(2.94)
Cash, $m
Cash, $m	Operating cash flow	(3)	(2)	(6)	(15)	(11)	(14)	(15)	(4)	0	(1)
	Capex	0	0	0	(1)	(1)	0	(1)	0	0	0
	Free cash flow	(3)	(2)	(6)	(17)	(12)	(14)	(16)	(5)	(1)	(2)
Balance, $m
Balance, $m	Working capital	(1)	2	11	12	16	30	11	3	(2)	3
	Total debt	1	0	0	0	2	0	0	0	—	—
	Net debt	1	(1)	(6)	(5)	(13)	(27)	(8)	(2)	(2)	(2)
	Shareholders’ equity	0	5	14	38	79	103	31	9	2	7
Returns, %
Returns, %	ROA	(77.22)	(40.00)	(3.73)	(92.08)	11.92	(22.02)	(89.43)	(94.55)	(57.54)	(41.67)
	ROIC	(495.92)	(3.43)	(14.91)	(28.48)	(16.70)	(16.17)	(205.28)	(194.30)	0.00	(27.22)
	ROE	(171.28)	(71.61)	(4.30)	(195.37)	20.95	(28.47)	(110.12)	(133.22)	(140.27)	(95.30)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INM InMed Pharmaceuticals Inc.	$7.3M	— (loss-making)	—	−26.22% (below 0%: shrinking)	n/m	−40.43% (below 0%: shrinking)	22.46%	0.00%	Compare
APUS Apimeds Pharmaceuticals US, Inc.	$6.6M	— (loss-making)	—	—	n/m	−67.94% (below 0%: shrinking)	—	0.00%	Compare
SNOA Sonoma Pharmaceuticals, Inc.	$5.5M	— (loss-making)	— (loss-making)	+59.55% (above 0%: growing)	n/m	+69.31% (above 0%: growing)	40.23%	(0.62%)	Compare
GELS Gelteq Limited	$4.6M	—	—	—	—	−40.15% (below 0%: shrinking)	—	—	Compare
RDHL Redhill Biopharma Ltd.	$4.4M	— (loss-making)	— (loss-making)	−90.32% (below 0%: shrinking)	n/m	−107.31% (below 0%: shrinking)	(7.52%)	0.00%	Compare
YCBD cbdMD, Inc.	$4.0M	41.2×	— (loss-making)	+20.55% (above 0%: growing)	n/m	+34.80% (above 0%: growing)	54.69%	(20.36%)
AKAN Akanda Corp.	$3.5M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
PRFX PainReform Ltd.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)	Compare
Median of peers	$4.5M	—	—	+12.73%	—	−40.29%	11.23%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

cbdMD, Inc. (YCBD) key facts

Concern: cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024.
cbdMD, Inc. (YCBD) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, YCBD traded at $0.35, a market capitalization of $4.0 million.
Return on equity was −95.3% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −21.65 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.